PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

NCT00328692 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

932

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure, Congestive

Interventions

DRUG: rolofylline
DRUG: Comparator: Placebo (unspecified)

Sponsor

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Collaborators

[object Object]